Hepatitis B surface antigen levels of cessation of nucleos(t)ide analogs associated with virological relapse in hepatitis B surface antigen-negative chronic hepatitis B patients

Table 2 Factors associated with virological relapse by Cox regression

Factors	Univariate analysis				Multivariate analysis1
	RR	Wald	95%CI	P value	RR	Wald	95%CI	P value
Age	0.996	0.285	0.981-1.011	0.592	0.996	0.231	0.980-1.012	0.996
Gender
Male	1				1
Female	0.914	0.298	0.662-1.262	0.585	0.956	0.061	0.067-1.364	0.805
Vertical transmission of infection history
Yes	1				1
No	1.064	0.155	0.782-1.448	0.694	1.063	0.139	0.769-1.470	0.71
Time to undetectable HBV DNA	1.041	1.162	0.967-1.121	0.281	1.069	1.644	0.965-1.184	0.2
Sustained time of antiviral	1.022	4.671	1.002-1.042	0.031	1.017	2.17	0.995-1.04	0.141
Drugs used		1.807		0.771		2.018		0.733
Lamivudine	1				1
Adefovir	1.011	0.002	0.614-1.666	0.964	0.834	0.427	0.485-1.436	0.514
Telbivudine	1.333	1.109	0.781-2.278	0.292	1.233	0.494	0.687-2.212	0.482
Entecavir	0.985	0.004	0.620-1.565	0.949	1.112	0.153	0.652-1.898	0.696
Lamivudine + Adefovir	0.991	0.001	0.589-1.667	0.973	0.872	0.228	0.496-1.531	0.633
Level of HBsAg at the end of therapy (LgIU/L)	1.971	6.542	1.172-3.316	0.011	2.041	5.303	1.098-3.194	0.021
Genotype
B	1				1
C	0.942	0.142	0.690-1.285	0.706	0.981	0.014	0.712-1.348	0.905

¹Cox regression, method: enter; If method is “stepwise”, only “Level of hepatitis B surface antigen (HBsAg) at the end of therapy” in the equation; RR = 1.971, 95%CI: 1.172-3.316, P = 0.011; 2Log likelihood = 1534.221. HBV: Hepatitis B virus.